Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (220)	6/5/1998 3:49:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Harvard Sci Says Impotence Pdt Doesn't Require Refrigeration June 05, 1998 3:06 PM LAKE MARY, Fla. (Dow Jones)--Harvard Scientific Corp. (HVSF) said results from an ongoing stability study for its patented lyophilized liposomal Prostaglandin E-1, an impotence treatment, have shown that it remains stable at room temperature for at least 12 months without any degradation of the active drug agent. In a press release Friday, the company said the study is "further proof that its product will become the treatment of choice by physicians and their sexual dysfunction patients." The company said the convenience of not having to refrigerate gives it a competitive advantage over other intrameatal delivery treatment products due to cost savings in its manufacturing and distribution practices. Sees As 'Medical Standard' The company believes Prostaglandin E-1 "is the most effective treatment" for male and female sexual dysfunction, and that it will be "the accepted medical standard" once results from its clinical trials are released. If it comes to market, Harvard Scientific's treatment would compete with Pfizer Inc.'s (PFE) Viagra, which has achieved blockbuster sales since its release in March despite recent reports that it is potentially life-threatening in some patients. The company said it is "confident" clinical trials of the drug will prove successful, and, if it receives marketing approval, that patients will accept the product "as their treatment of choice." On June 1, Harvard Scientific received Food & Drug Administrative clearance for Phase II clinical trials of the treatment. In 1995, the Prostaglandin drug received FDA approval for use in Pharmacia & Upjohn Inc.'s (PNU) Caverject, an erectile dysfunction treatment administered by needle injection.